BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,070 filers reported holding BAXTER INTL INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $457,000 | +35.6% | 5,279 | +25.8% | 0.02% | +26.3% |
| Q3 2021 | $337,000 | 0.0% | 4,195 | +0.0% | 0.02% | 0.0% |
| Q2 2021 | $337,000 | -4.0% | 4,194 | +0.6% | 0.02% | -13.6% |
| Q1 2021 | $351,000 | +1.4% | 4,169 | -3.5% | 0.02% | -4.3% |
| Q4 2020 | $346,000 | -0.3% | 4,319 | 0.0% | 0.02% | -14.8% |
| Q3 2020 | $347,000 | -6.5% | 4,319 | 0.0% | 0.03% | -12.9% |
| Q2 2020 | $371,000 | +6.0% | 4,319 | 0.0% | 0.03% | -8.8% |
| Q1 2020 | $350,000 | -3.0% | 4,319 | +0.0% | 0.03% | +17.2% |
| Q4 2019 | $361,000 | -4.2% | 4,318 | 0.0% | 0.03% | -12.1% |
| Q3 2019 | $377,000 | +4.4% | 4,318 | -2.3% | 0.03% | +6.5% |
| Q2 2019 | $361,000 | +4.9% | 4,418 | +4.3% | 0.03% | -3.1% |
| Q1 2019 | $344,000 | +30.3% | 4,235 | +6.0% | 0.03% | +10.3% |
| Q4 2018 | $264,000 | -82.5% | 3,996 | -79.6% | 0.03% | -81.8% |
| Q3 2018 | $1,507,000 | -2.6% | 19,552 | -6.8% | 0.16% | -3.6% |
| Q2 2018 | $1,548,000 | +6.8% | 20,975 | -5.9% | 0.16% | +3.8% |
| Q1 2018 | $1,449,000 | -8.6% | 22,283 | -9.2% | 0.16% | -8.1% |
| Q4 2017 | $1,585,000 | -2.9% | 24,532 | -5.8% | 0.17% | -7.0% |
| Q3 2017 | $1,633,000 | 0.0% | 26,047 | -3.5% | 0.19% | -5.6% |
| Q2 2017 | $1,633,000 | +15.2% | 26,984 | -1.2% | 0.20% | +8.8% |
| Q1 2017 | $1,417,000 | +7.8% | 27,323 | -7.9% | 0.18% | -3.7% |
| Q4 2016 | $1,315,000 | -11.0% | 29,673 | -4.4% | 0.19% | -15.3% |
| Q3 2016 | $1,477,000 | -0.9% | 31,032 | -5.8% | 0.22% | -10.8% |
| Q2 2016 | $1,490,000 | +8.1% | 32,956 | -1.8% | 0.25% | -2.7% |
| Q1 2016 | $1,378,000 | +6.0% | 33,562 | -1.5% | 0.26% | -5.5% |
| Q4 2015 | $1,300,000 | +4.0% | 34,078 | -3.0% | 0.27% | -2.2% |
| Q3 2015 | $1,250,000 | -41.9% | 35,137 | +14.2% | 0.28% | -42.4% |
| Q2 2015 | $2,152,000 | +227.1% | 30,774 | +220.2% | 0.48% | +66.4% |
| Q1 2015 | $658,000 | +25.6% | 9,612 | +28.6% | 0.29% | -13.5% |
| Q4 2014 | $524,000 | -44.8% | 7,472 | -44.3% | 0.33% | +14.0% |
| Q3 2014 | $949,000 | +12.0% | 13,422 | +14.6% | 0.29% | +23.6% |
| Q2 2014 | $847,000 | +3.5% | 11,717 | +5.4% | 0.24% | -11.6% |
| Q1 2014 | $818,000 | +20.5% | 11,112 | +13.7% | 0.27% | +11.2% |
| Q4 2013 | $679,000 | +19.3% | 9,769 | +12.6% | 0.24% | +12.6% |
| Q3 2013 | $569,000 | +366.4% | 8,674 | +390.3% | 0.21% | +256.7% |
| Q2 2013 | $122,000 | – | 1,769 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |